
CANF Stock Forecast & Price Target
CANF Analyst Ratings
Bulls say
Can Fite Biopharma is a clinical-stage biopharmaceutical company focused on developing small-molecule drugs targeting the A3 adenosine receptor. They have a strong pipeline with promising drugs in Phase II and III development, including Namodenoson, Piclidenoson, and CF602. The company recently announced positive Phase 2a data for Namodenoson in pancreatic cancer and plans to pursue a combination immunotherapy strategy in a Phase 2b study. This, along with confidential partnerships in place, validates the potential of their programs and could attract industry attention. With a solid financial position, including $12.8M in net cash, and a projected value of $375M, we maintain a Buy rating and increase our 12-month price target to $8.00 per ADS. Risks include commercial, clinical, regulatory, legal, intellectual property, competition, and dilution.
Bears say
Can Fite Biopharma is currently in clinical trials for its pipeline of drugs targeting the A3AR receptor which have shown encouraging survival data in pancreatic ductal adenocarcinoma (PDAC), a difficult-to-treat cancer. However, the company's financials are concerning, with a net loss of $7.6 million in the first quarter of 2021 and a significant decrease in total assets from $38.4 million in 2020 to $13.1 million in 2021. This, combined with the competitive landscape of the biopharmaceutical industry and the limited data available on Can Fite's drugs, suggests a negative outlook on the stock at this time.
This aggregate rating is based on analysts' research of Can-Fite BioPharma Ltd. and is not a guaranteed prediction by Public.com or investment advice.
CANF Analyst Forecast & Price Prediction
Start investing in CANF
Order type
Buy in
Order amount
Est. shares
0 shares